Abcellera Biologics is trading 6% up at $12.37, primarily supported by a 2.55% biotech-sector rally and stronger market sentiment following the Federal Reserve decision.
- No new company-specific announcement was identified for September 17, 2026.
- The investor-relations page lists no September 16–17 release.
- The latest relevant clinical update was the August 10 positive ABCL635 Phase 2 announcement.